SGLT2iのイメージも作ってみたんじゃ

10 127

CHERNEY: Characteristics of participants enrolled in renal outcome trials involving SGLT2 inhibitors

EMPA-KIDNEY ⏳⌛️
🔲 +/- Type 2 DM (T2D)
🔲 eGFR ~ 20
🔲 Low levels of albuminuria
🇲🇾

👉 https://t.co/R8rVmrqwAf

20 35

CHERNEY: Characteristics of participants enrolled in renal outcome trials involving SGLT2 inhibitors

EMPA-KIDNEY (still ongoing)
🔲 +/- Type 2 Diabetes
🔲 eGFR ~ 20
🔲 Low levels of albuminuria


https://t.co/VEBssUX9pV

4 5

Our November issue is now live online, featuring hormone therapy, receptor agonists & inhibitors in disease, metabolic health in the region, familial & & more https://t.co/ft8CFDeSQz

7 17